Loading company…
PetMedix develops biopharmaceutical treatments for companion animals.
Founded in 2017 and based in Babraham, Cambridge, PetMedix develops biopharmaceuticals, including monoclonal antibodies, for companion animals. Zoetis acquired the company in September 2023 for USD 111.00 mn, with an additional payment of approximately USD 100 mn tied to milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in